Protection against Mycobacterium leprae Infection by the ID83/GLA-SE and ID93/GLA-SE Vaccines Developed for Tuberculosis
Open Access
- 1 September 2014
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 82 (9) , 3979-3985
Abstract
Despite the dramatic reduction in the number of leprosy cases worldwide in the 1990s, transmission of the causative agent, Mycobacterium leprae , is still occurring, and new cases continue to appear. New strategies are required in the pursuit of leprosy elimination. The cross-application of vaccines in development for tuberculosis may lead to tools applicable to elimination of leprosy. In this report, we demonstrate that the chimeric fusion proteins ID83 and ID93, developed as antigens for tuberculosis (TB) vaccine candidates, elicited gamma interferon (IFN-γ) responses from both TB and paucibacillary (PB) leprosy patients and from healthy household contacts of multibacillary (MB) patients (HHC) but not from nonexposed healthy controls. Immunization of mice with either protein formulated with a Toll-like receptor 4 ligand (TLR4L)-containing adjuvant (glucopyranosyl lipid adjuvant in a stable emulsion [GLA-SE]) stimulated antigen-specific IFN-γ secretion from pluripotent Th1 cells. When immunized mice were experimentally infected with M. leprae , both cellular infiltration into the local lymph node and bacterial growth at the site were reduced relative to those of unimmunized mice. Thus, the use of the Mycobacterium tuberculosis candidate vaccines ID83/GLA-SE and ID93/GLA-SE may confer cross-protection against M. leprae infection. Our data suggest these vaccines could potentially be used as an additional control measure for leprosy.Keywords
This publication has 27 references indexed in Scilit:
- The Importance of Adjuvant Formulation in the Development of a Tuberculosis VaccineThe Journal of Immunology, 2012
- Advances and hurdles on the way toward a leprosy vaccineHuman Vaccines, 2011
- A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosisScience Translational Medicine, 2010
- The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in AdultsAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Integration of Leprosy Elimination into Primary Health Care in Orissa, IndiaPLOS ONE, 2009
- Vaccination with the ML0276 Antigen Reduces Local Inflammation but Not Bacterial Burden during Experimental M ycobacterium leprae InfectionInfection and Immunity, 2009
- Intradermal immunization improves protective efficacy of a novel TB vaccine candidateVaccine, 2009
- Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeysProceedings of the National Academy of Sciences, 2009
- Antigen-Specific Cellular and Humoral Responses Are Induced by Intradermal Mycobacterium leprae Infection of the Mouse EarInfection and Immunity, 2007
- Massive gene decay in the leprosy bacillusNature, 2001